ArticleJPRAS open2026
Serum tryptase and IgE before and after explantation in women with breast implant illness.
Article in JPRAS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast Implant Illness (BII) is characterized by systemic and local symptoms in a subset of women with silicone breast implants, but its pathophysiology remains unclear. Mast cell activation has been proposed as an underlying mechanism, yet systemic mast cell-related biomarkers have not been systematically evaluated in this context. This study aimed to assess whether explantation is associated with changes in serum tryptase and total IgE in women with BII. Methods: Seventy-one women with BII at a tertiary outpatient clinic provided paired blood samples before and after explantation (median interval, 8 months). Serum tryptase was measured by enzyme-linked fluorescence assay and total immunoglobulin E (IgE) by ImmunoCAP/EliA. Paired changes were analyzed in the overall cohort and in baseline-defined subgroups, including allergy status and pre-explantation IgE >100 kU/L. Results: In the full cohort, neither serum tryptase nor total IgE changed significantly after explantation (median differences: +0.09 ng/mL and -1.2 kU/L, respectively; both p > 0.1). Among 13 women with high baseline IgE (>100 kU/L), nine showed declines (median -118 kU/L), whereas tryptase levels remained unchanged and within normal limits. Of five women with elevated baseline tryptase (>11.4 ng/mL), three showed decreases after explantation, but only one normalized. Conclusions: These findings show no evidence of explantation-associated changes in serum tryptase in women with Breast Implant Illness. Total IgE levels showed no consistent change overall, although heterogeneous post-explantation IgE changes were observed in a small subgroup with elevated baseline IgE. Mast cell involvement in BII cannot be excluded, as local mast cell activity and other mast-cell-derived mediators were not assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.